Search Results - targeted+protein+degradation

6 Results Sort By:
Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers
SHORT DESCRIPTION Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Yanis Boumber * Principal Investigator NU Tech ID: NU 2023-140 IP STATUS U.S....
Published: 6/16/2026   |   Updated: 6/16/2026   |   Inventor(s):  
Keywords(s): BIO2026, Cancer/Oncology, Head and neck cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics
NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036) INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* SHORT DESCRIPTION MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders. BACKGROUND Leukemia and brain...
Published: 6/16/2026   |   Updated: 4/29/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, BIO2026, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
SHORT DESCRIPTION A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets. INVENTORS Shana Kelley* Weinberg College of Arts & Sciences, Department of Chemistry Yi Li * Principal Investigator NU Tech ID: NU 2025-050 IP...
Published: 6/16/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 6/16/2026   |   Updated: 3/5/2026   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Northwestern University Feinberg School of Medicine, Department of Urology Gary Schiltz (PI)* Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 6/16/2026   |   Updated: 2/3/2026   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137 INVENTORS Derek Wainwright* Gary Schiltz SHORT DESCRIPTION IDO-PROTAC that target immunosuppressive IDO activity via degradation ABSTRACT The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 6/16/2026   |   Updated: 5/27/2022   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics